Literature DB >> 21131983

Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi.

Johannes Zuber1, Katherine McJunkin, Christof Fellmann, Lukas E Dow, Meredith J Taylor, Gregory J Hannon, Scott W Lowe.   

Abstract

Short hairpin RNAs (shRNAs) are versatile tools for analyzing loss-of-function phenotypes in vitro and in vivo. However, their use for studying genes involved in proliferation and survival, which are potential therapeutic targets in cancer and other diseases, is confounded by the strong selective advantage of cells in which shRNA expression is inefficient. We therefore developed a toolkit that combines Tet-regulated miR30-shRNA technology, robust transactivator expression and two fluorescent reporters to track and isolate cells with potent target knockdown. We demonstrated that this system improves the study of essential genes and was sufficiently robust to eradicate aggressive cancer in mice by suppressing a single gene. Further, we applied this system for in vivo negative-selection screening with pooled shRNAs and propose a streamlined, inexpensive workflow that will facilitate the use of RNA interference (RNAi) for the identification and evaluation of essential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21131983      PMCID: PMC3394154          DOI: 10.1038/nbt.1720

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  31 in total

1.  Transcriptional Silencing of Retroviral Vectors.

Authors:  A.H. Lund; M. Duch; F.S. Pedersen
Journal:  J Biomed Sci       Date:  1996 Nov-Dec       Impact factor: 8.410

2.  A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression.

Authors:  Kum-Joo Shin; Estelle A Wall; Joelle R Zavzavadjian; Leah A Santat; Jamie Liu; Jong-Ik Hwang; Robert Rebres; Tamara Roach; William Seaman; Melvin I Simon; Iain D C Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

3.  Retrovirus silencing by an epigenetic TRIM.

Authors:  James Ellis; Akitsu Hotta; Mojgan Rastegar
Journal:  Cell       Date:  2007-10-05       Impact factor: 41.582

4.  Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators.

Authors:  M J Pikaart; F Recillas-Targa; G Felsenfeld
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

5.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

6.  A loss-of-function RNA interference screen for molecular targets in cancer.

Authors:  Vu N Ngo; R Eric Davis; Laurence Lamy; Xin Yu; Hong Zhao; Georg Lenz; Lloyd T Lam; Sandeep Dave; Liming Yang; John Powell; Louis M Staudt
Journal:  Nature       Date:  2006-03-29       Impact factor: 49.962

Review 7.  Applications of RNA interference in mammalian systems.

Authors:  Scott E Martin; Natasha J Caplen
Journal:  Annu Rev Genomics Hum Genet       Date:  2007       Impact factor: 8.929

8.  Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness.

Authors:  Siamak Agha-Mohammadi; Mark O'Malley; Abrak Etemad; Zhong Wang; Xiao Xiao; Michael T Lotze
Journal:  J Gene Med       Date:  2004-07       Impact factor: 4.565

9.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

10.  Viral evolution as a tool to improve the tetracycline-regulated gene expression system.

Authors:  Atze T Das; Xue Zhou; Monique Vink; Bep Klaver; Koen Verhoef; Giuseppe Marzio; Ben Berkhout
Journal:  J Biol Chem       Date:  2004-02-02       Impact factor: 5.157

View more
  156 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Authors:  Benjamin Mizukawa; Eric O'Brien; Daniel C Moreira; Mark Wunderlich; Cindy L Hochstetler; Xin Duan; Wei Liu; Emily Orr; H Leighton Grimes; James C Mulloy; Yi Zheng
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

3.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Authors:  Peter M Bruno; Yunpeng Liu; Ga Young Park; Junko Murai; Catherine E Koch; Timothy J Eisen; Justin R Pritchard; Yves Pommier; Stephen J Lippard; Michael T Hemann
Journal:  Nat Med       Date:  2017-02-27       Impact factor: 53.440

4.  Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.

Authors:  Luisa F Escobar-Hoyos; Alex Penson; Ram Kannan; Hana Cho; Chun-Hao Pan; Rohit K Singh; Lisa H Apken; G Aaron Hobbs; Renhe Luo; Nicolas Lecomte; Sruthi Babu; Fong Cheng Pan; Direna Alonso-Curbelo; John P Morris; Gokce Askan; Olivera Grbovic-Huezo; Paul Ogrodowski; Jonathan Bermeo; Joseph Saglimbeni; Cristian D Cruz; Yu-Jui Ho; Sharon A Lawrence; Jerry P Melchor; Grant A Goda; Karen Bai; Alessandro Pastore; Simon J Hogg; Srivatsan Raghavan; Peter Bailey; David K Chang; Andrew Biankin; Kenneth R Shroyer; Brian M Wolpin; Andrew J Aguirre; Andrea Ventura; Barry Taylor; Channing J Der; Daniel Dominguez; Daniel Kümmel; Andrea Oeckinghaus; Scott W Lowe; Robert K Bradley; Omar Abdel-Wahab; Steven D Leach
Journal:  Cancer Cell       Date:  2020-06-18       Impact factor: 31.743

5.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

Authors:  Stefan P Glaser; Erinna F Lee; Evelyn Trounson; Philippe Bouillet; Andrew Wei; W Douglas Fairlie; David J Izon; Johannes Zuber; Amy R Rappaport; Marco J Herold; Warren S Alexander; Scott W Lowe; Lorraine Robb; Andreas Strasser
Journal:  Genes Dev       Date:  2012-01-15       Impact factor: 11.361

6.  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

Authors:  Evangelia Loizou; Ana Banito; Geulah Livshits; Yu-Jui Ho; Richard P Koche; Francisco J Sánchez-Rivera; Allison Mayle; Chi-Chao Chen; Savvas Kinalis; Frederik O Bagger; Edward R Kastenhuber; Benjamin H Durham; Scott W Lowe
Journal:  Cancer Discov       Date:  2019-05-08       Impact factor: 39.397

7.  The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.

Authors:  Nina Fenouille; Christopher F Bassil; Issam Ben-Sahra; Lina Benajiba; Gabriela Alexe; Azucena Ramos; Yana Pikman; Amy S Conway; Michael R Burgess; Qing Li; Frédéric Luciano; Patrick Auberger; Ilene Galinsky; Daniel J DeAngelo; Richard M Stone; Yi Zhang; Archibald S Perkins; Kevin Shannon; Michael T Hemann; Alexandre Puissant; Kimberly Stegmaier
Journal:  Nat Med       Date:  2017-02-13       Impact factor: 53.440

8.  The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.

Authors:  Hubo Li; Brenton G Mar; Huadi Zhang; Rishi V Puram; Francisca Vazquez; Barbara A Weir; William C Hahn; Benjamin Ebert; David Pellman
Journal:  Blood       Date:  2016-10-18       Impact factor: 22.113

9.  HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Authors:  Yuqing Sun; Bo Zhou; Fengbiao Mao; Jing Xu; Hongzhi Miao; Zhenhua Zou; Le Tran Phuc Khoa; Younghoon Jang; Sheng Cai; Matthew Witkin; Richard Koche; Kai Ge; Gregory R Dressler; Ross L Levine; Scott A Armstrong; Yali Dou; Jay L Hess
Journal:  Cancer Cell       Date:  2018-09-27       Impact factor: 31.743

10.  Therapeutic vaccination with 4-1BB co-stimulation eradicates mouse acute myeloid leukemia.

Authors:  Daniel Kerage; Megan S F Soon; Brianna L Doff; Takumi Kobayashi; Michael D Nissen; Pui Yeng Lam; Graham R Leggatt; Stephen R Mattarollo
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.